Shockwave Medical grows sales 193% in Q1

Shockwave Medical (NSDQ:SWAV) this week posted first-quarter results that beat the overall consensus on Wall Street.

The Santa Clara, California-based company reported profits of $14.5 million, or 39¢ per share, on sales of $93.6 million for the three months ended March 31, for a bottom-line gain from the year prior on sales growth of 193.5%.

Earnings per share were 25¢ ahead of The Street, where analysts were looking for sales of $84.2 million.

“Our growth this quarter was driven by strong execution from our teams across the globe, despite the myriad geopolitical, health and economic challenges that continue to face us all,” CEO and President Doug Godshall said in a news release. “The exceptional progress that the Shockwave team has made this quarter continues to demonstrate what an important solution IVL has become for patients who suffer from calcified arterial disease. We look forward to continuing to partner with our customers to help them enh…

Read more
  • 0

Shockwave Medical up on 270% sales growth in Q4

Shockwave Medical (NSDQ:SWAV) this week posted fourth-quarter results that beat the overall consensus on Wall Street.

The Santa Clara, California-based company reported profits of $12.9 million, or 34¢ per share, on sales of $84.2 million, for the three months ended Dec. 31, 2021, for a bottom-line gain of 181% on sales growth of 270.6% compared with Q4 2020.

Earnings per share were 34¢, 25¢ ahead of The Street, where analysts were looking for sales of $75.4 million.

“I continue to be humbled by the exceptional performance of the entire Shockwave team, despite the unpredictable and unprecedented challenges that are constantly being put in front of us,” president and CEO Doug Godshall said in a news release. “2021 was another stellar year with significant achievements across the board – from regulatory and sales to reimbursement, marketing, and operations. I want to thank our employees for their hard work and persistence in helping us achieve these …

Read more
  • 0

Shockwave Medical rises on Street-beating Q2, raised guidance

Shockwave Medical (NSDQ:SWAV) shares ticked up today on second-quarter results that topped the consensus forecast.

The Santa Clara, Calif.-based company posted losses of -$425,000 on sales of $55.9 million for the three months ended June 30, 2021, for a 97.7% bottom-line gain thanks to the company’s revenues multiplying by more than five times year-over-year.

Earnings per share came in at -1¢, 40¢ ahead of Wall Street, where analysts were looking for sales of $45.2 million.

“Our second-quarter results reflect the continued hard work and perseverance of our teams across the globe in not only launching our Shockwave C2 device in the United States, but in achieving exceptional results across our entire product portfolio and operational infrastructure throughout the Shockwave organization. Our business showed substantial growth, despite the challenges related to the COVID-19 pandemic,” Shockwave president & CEO Doug Godshall said in a n…

Read more
  • 0

Shockwave Medical stock up nearly 21%

Shockwave Medical (NSDQ:SWAV) posted first-quarter results that beat the revenue consensus on Wall Street but missed earnings estimates.

Shockwave Medical, though, also said it projects revenue for the full year to roughly triple to between $195–205 million — representing 188–202% growth over the prior year’s revenue.

The Santa Clara, Calif.-based— which has proprietary cardiovascular disease treatment tech involving local delivery of sonic pressure — saw  SWAV shares rise nearly 21% to 163.10 apiece by the late afternoon today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was down slightly.

Shockwave Medical reported losses of -$23.6 million, or -68¢ per share, on sales of $31.9 million for the three months ended March 31, for a sales growth of 109.91% compared with Q1 2020, which reported losses of -$18.775 million and sales of $15.197 million.

Earnings per share were -68¢, 24¢ be…

Read more
  • 0

This telemedicine system could get medtech sales reps back to ORs

[Image courtesy of Avail Medsystems]

Daniel Hawkins’ surprise isn’t a matter of what, but when.

The successful medtech executive and former Shockwave Medical CEO fully expected medical device makers would see Avail Medsystem’s telemedicine system as a more efficient way for sales reps to sit in on surgeries.

By Hawkins’ projections, Avail’s system would eliminate much of the time sales reps take traveling from operating room to operating room by allowing them to communicate with surgeons via camera and audio connections.

But Hawkins still didn’t expect demand for the system to come this quickly because no one could have predicted a pandemic.

“We would have been where we are today in three to four years,” Hawkins said in an interview with MassDevice. “What COVID-19 did was speed it all up … COVID put a white-hot spotlight on a problem that was already there.”

Avail’s solution is …

Read more
  • 0

Shockwave ticks up on Street-beating Q2

Shockwave Medical (NSDQ:SWAV) shares got a slight boost today on second-quarter results that topped the consensus forecast.

The Santa Clara, Calif.-based calcified coronary lesions treatment developer posted losses of -$18.1 million, or -56¢ per share, on sales of $10.3 million for the three months ended June 30, 2020, for a -70.8% bottom-line slide on sales growth of 2.7%.

Shockwave’s adjusted EPS of -56¢ came in 6¢ ahead of Wall Street projections, while the company’s revenue performance topped estimates by 6%.

“The progress we made during this past quarter, despite the hurdles and challenges of COVID-19, reflects the commitment and strength of our team and the uniqueness of our proprietary IVL technology,” Shockwave president & CEO Doug Godshall said in a news release. “The continued interest and demand for IVL has really demonstrated how highly valued Shockwave’s technology continues to be as a safe, effective, efficient option for ou…

Read more
  • 0